05.01.02
Pharmaceutical company Novogen Limited, Stamford, CT, has been granted a U.S. patent to cover the use of the isoflavone, formononetin, in the treatment and prevention of osteoporosis. In studies recently conducted by the University of Sydney researchers Dr. Meloni Muir and associate professor Rebecca Mason, red clover derived formononetin was shown to have the potential to promote bone growth by increasing the metabolic activity of bone forming cells.